echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 97 big varieties of winning ways

    97 big varieties of winning ways

    • Last Update: 2019-12-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 18, the document No 73 issued by the state health insurance bureau and the health and Health Commission officially promoted the sustainable development of the pharmaceutical industry at the national level, with clear objectives, "to promote the implementation of national health insurance negotiation drugs in 2019 as soon as possible, so as to ensure that the majority of insured patients can enjoy the relevant treatment as scheduled" This measure will catalyse 97 large varieties of medical insurance negotiation and reshape the pattern of clinical medication Recently, the people's network issued a new document to "promote the implementation of national medical insurance negotiation drugs as soon as possible", according to the 2020 medical insurance catalog, there are still 12 days to implement The clinical varieties in China have remained stable basically There has been no qualitative change in the past decade They are all affiliated to several large pharmaceutical enterprises, such as Pfizer, Yangzi River, Sanofi, AstraZeneca, etc Pfizer is the most eye-catching of the top ten, occupying two seats The threshold of the top ten clubs has been raised to 5 billion yuan According to the data, the terminal sales of salvianolic acid salt for injection of the 10th Shanghai Green Valley Pharmaceutical Co., Ltd in 2017 totaled 4.89 billion yuan The top ten clinical varieties come from five treatment fields, namely, cardio cerebrovascular, analgesia, anti infection, respiration and tumor Among them, six places were taken away from cardiovascular and cerebrovascular products, more than half of them According to the calculation of 5 billion yuan, the sales volume of cardiovascular and cerebrovascular products accounts for more than 60%, which is contrary to the emphasis of clinical rational drug use The characteristics of these large varieties: for many years, the company has maintained billions of sales and covered many hospitals with favorable policies For example, with the help of more than 12900 AstraZeneca standard atomizing rooms, the company has successfully pushed the company to the first-line treatment Not only in large hospitals, but also in many community hospitals as the first choice treatment plan The implementation of medical insurance may not be possible From the evaluation of the implementation of the three medical insurance negotiation directories in 31 provinces and cities, only 7 provinces and cities have achieved good implementation, while others are good, poor and poor Among them, the health and Health Commission issued two documents requiring hospitals not to influence the supply guarantee and rational drug demand of negotiated drugs on the grounds of total control of medical expenses, total control of medical insurance expenses, "drug proportion" and limit of drug varieties; only four provinces and cities issued documents and negotiated drugs did not account for total control of expenses, and 22 provinces and cities issued documents did not include drug proportion Therefore, it is particularly important for the negotiation drugs to benefit the people 97 negotiation varieties entered the national medical insurance catalog through substantial price reduction, and the Bureau / Commission Document No 73 guaranteed their growth From the perspective of this medical insurance negotiation, the key assessment varieties are more than 10 clinical treatment fields involving cancer, rare diseases, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular, digestion, etc., as well as major domestic innovative varieties These varieties cover more fields and are also clinically necessary 97 negotiation catalogue products, basically with low price, exclusive and historical mission, make people have the characteristics of sense of gain With the strong return of China's pharmaceutical research and development, China's innovative drugs will affect global pharmaceutical research and development in the future After 2013, 250000 R & D talents in China's pharmaceutical field will flow back, greatly ensuring the talent echelon construction of China's R & D Lingteng pharmaceutical was established in 2017 Recently, it submitted the clinical application of cardosol double anti drug, becoming the first double anti drug in the world Even innovative drugs need to have Chinese characteristics and conform to the national medical reform strategy There is a "patent cliff" in the foreign pharmaceutical industry, that is, the price of drugs remains high within the patent period, helping pharmaceutical companies recover high R & D costs Once the patent expires, the price "precipice" falls This is different in China During the patent period, price reduction is also needed, only for the benefit of the people For example, "4.4 is too bad" dagliejing experienced the experience that the lowest price in the world continues to be cut The first national centralized procurement and the first nationwide health care negotiation will promote the completion of the most brilliant stroke of China's health care reform The shortlisted varieties mean getting national endorsement The national negotiation of 97 major varieties also lays the foundation for the continuous expansion of the medical insurance catalogue with Chinese characteristics 1 Large varieties shoulder the national mission to help solve the problem of expensive medical treatment The average price reduction of large varieties is more than 60%, which is also the first large-scale collective price reduction of national medical insurance catalog products These large varieties will be landed in time, which will save treatment costs for patients to a certain extent, and help medical reform to solve the overall goal of "expensive medical treatment" 2 The growth of large varieties and the promotion of clinical rational drug use 97 large varieties of medical insurance negotiation are clinically necessary products with good efficacy and safety The rapid growth and development of these products will change the structure of clinical medication to a certain extent, promote the rational use of therapeutic drugs, and reduce the proportion of auxiliary drugs 3 During the patent period, the price is also reduced This is a medical insurance reimbursement system with Chinese characteristics The unique feature of this healthcare negotiation is the price reduction of patented products, which is different from the healthcare and medical reimbursement models of most countries in the world Most European and American countries are "patent cliff", and the price level of products within the patent period remains high In China, not only the "patent cliff" is promoted through national centralized procurement, but also the "price reduction of products within the patent period" reflects the medical insurance reimbursement system with Chinese characteristics During the patent period, price reduction will explore a new way for the future medical reform, and carry out top-level design from the perspective of the benefits of the state, enterprises and patients, so as to achieve a win-win situation among the three parties The way to win for a large variety of products, such as hanging net, entering hospital and replacing, will fulfill the mission given by the state Liu Qian said that speed is everything No matter how fast you hang the net, enter the court or replace it, it's only 730 days from the beginning to the end of the game 1 97 large varieties directly linked to the Internet According to the time limit stipulated by the Ministry of human resources and social security of the State Health Insurance Bureau on the inclusion of negotiation drugs in 2019 (medical insurance Fa [2019] No 65), 97 negotiation drugs will be directly linked to the provincial drug centralized purchase platform This means that the country saves time for varieties to enter the clinical practice, which can be implemented on January 1, 2020 According to the Beijing Sunshine procurement platform, Pfizer's tofacib, a new negotiating product, was admitted to three hospitals in Beijing at the price of medical insurance 2 97 large varieties directly entered the hospital Today, people's daily issued a document to "promote the implementation of national medical insurance negotiation drugs as soon as possible" The second point pointed out that promoting the negotiation drugs to enter designated medical institutions in time Local medical insurance, health and other departments shall, according to their duties, put forward specific requirements for the allocation and use of negotiated drugs, and guide designated medical institutions to allocate and use drugs in a timely and reasonable manner according to their functional orientation, clinical needs and diagnosis and treatment capabilities From the documents issued by the medical insurance bureau and the health care commission to the interpretation of the people's website documents, it is once again clear that the state's further management of the drug directory of medical institutions is reflected in "timely access" at the same time Beijing medical institutions have been at the forefront in responding to the implementation of national policies It is reported that several top three hospitals in Beijing have started preparations for pharmaceutical conferences, will complete the bill of lading in December, and a number of foreign medical insurance negotiation products have submitted the drug demand list to the pharmaceutical Committee of the hospital Another hospital with a long history in the core area of Beijing has adopted the policy of "one entry, one withdrawal", that is, an enterprise needs to apply for a variety to withdraw from the drug catalog of the hospital With the implementation of the negotiation catalog, the hospital opens a "green channel" for the negotiation drugs 3 Direct replacement of 97 large varieties authorized by the state
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.